Phase 1 trial of a selective orexin 1 receptor antagonist ACT-539313 in healthy male subjects: A first-in-human randomized, double-blind single-ascending dose study

Trial Profile

Phase 1 trial of a selective orexin 1 receptor antagonist ACT-539313 in healthy male subjects: A first-in-human randomized, double-blind single-ascending dose study

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2018

At a glance

  • Drugs ACT 539313 (Primary)
  • Indications Anxiety disorders
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 24 Mar 2018 Status changed from recruiting to completed according to results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 29 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top